Twist Bioscience Stock Surges Over 31% After Partnership With Eli Lilly's TuneLab
Biotech stock Twist Bioscience (NASDAQ: TWST) surged over 31% for the week after announcing a partnership with Eli Lilly’s advanced drug discovery initiative, TuneLab. The collaboration involves Twist providing antibody characterization data services using its AbLab model to help screen candidate molecules efficiently. The agreement allows participants in TuneLab—Eli Lilly's AI and machine learning platform—to access high-quality data while contributing back for federated training. CEO Emily Leproust highlighted the benefits of flexible protocols, pricing options, and improved efficiency from this partnership. Analysts view the deal as a win-win scenario that could boost Twist’s revenue and enhance its role in drug discovery. The move also reflects broader optimism about biotech innovation driven by AI.
Topics: artificial intelligence partnerships pharmaceuticals